Neluxicapone

Neluxicapone
Clinical data
Drug class	Catechol O-methyltransferase inhibitor
Identifiers
	IUPAC name 4,5-dihydroxy-2-[(4-methylphenyl)methyl]benzene-1,3-dicarbonitrile;
CAS Number	1498323-18-4;
PubChem CID	90015465;
ChemSpider	68007328;
UNII	ZO0K3RUH9L;
Chemical and physical data
Formula	C16H12N2O2
Molar mass	264.284 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC=C(C=C1)CC2=C(C(=C(C=C2C#N)O)O)C#N;
	InChI InChI=1S/C16H12N2O2/c1-10-2-4-11(5-3-10)6-13-12(8-17)7-15(19)16(20)14(13)9-18/h2-5,7,19-20H,6H2,1H3; Key:GILLLKMLIBNDKV-UHFFFAOYSA-N;

Neluxicapone (INNTooltip International Nonproprietary Name) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024.^[1]^[2]^[3] The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone.^[4]^[3] COMT inhibitors are used in conjunction with levodopa in the treatment of Parkinson's disease.^[4] Neluxicapone was first described in the literature by 2018.^[3]^[1] Its INNTooltip International Nonproprietary Name was designated by the World Health Organization (WHO) in 2019.^[2]

References

^ ^a ^b The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2018 (StemBook2018) (PDF). World Health Organization. 2018. No. WHO/EMP/RHT/TSN/2018.1. -capone catechol-O-methyltransferase (COMT) inhibitors. entacapone (65), nebicapone (96), neluxicapone (119), nitecapone (62), opicapone (103), tolcapone (66)
^ ^a ^b World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81" (PDF). WHO Drug Information. 33 (1): 43–133.
^ ^a ^b ^c "Neluxicapone". PubChem. U.S. National Library of Medicine. Retrieved 8 October 2024.
^ ^a ^b Haasio K (2010). "Toxicology and safety of COMT inhibitors". International Review of Neurobiology. 95: 163–189. doi:10.1016/B978-0-12-381326-8.00007-7. ISBN 978-0-12-381326-8. PMID 21095462.